Scarica l'app Stockscreener
27.74
6.41%
-1.90
Dopo l'orario di chiusura:
27.74
Pharvaris Nv Borsa (PHVS) Ultime notizie
Pharvaris N.V. (PHVS) stock price, news, quote and history - Yahoo Finance Singapore
Pharvaris N.V. (PHVS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet - GlobeNewswire Inc.
Pharvaris N.V. (PHVS) stock price, news, quote and history - Yahoo Finance Australia
Pharvaris N.V. (PHVS) stock price, news, quote and history - Yahoo Finance UK
Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy - GlobeNewswire Inc.
Pharvaris (PHVS) Shares Edge Higher, Holding Firmly Above Key SupportSMA Signal - siam.in
Form 4 Pharvaris N.V. For: 26 September By Investing.com - Investing.com Nigeria
A Pharvaris (PHVS) director proposes selling shares valued at $395,524. - Stock Titan
Form 4 Pharvaris N.V. For: 23 September By Investing.com - Investing.com Nigeria
Form 4 Pharvaris N.V. For: 23 September By Investing.com - Investing.com Canada
Form 4 Pharvaris N.V. For: 23 September By Investing.com - Investing.com UK
Planned $7M Pharvaris (NASDAQ: PHVS) stock sale disclosed for founder shares - Stock Titan
After $7M stock sale, Pharvaris (NASDAQ: PHVS) director plans more - Stock Titan
Pharvaris (NASDAQ: PHVS) officer plans Rule 144 sale of 6,000 shares - Stock Titan
Pharvaris (PHVS) CEO buys 300,000 shares in rights exercise - Stock Titan
Pharvaris Chief Early Development Anne Lesage disposes of USD 765,466 in common shares - Bitget
Pharvaris Chief Early Development Anne Lesage disposes of USD 765,466 in common shares - Bitget
Pharvaris (NASDAQ: PHVS) officer to sell 100,000 shares under Rule 144 - Stock Titan
Shareholder at Pharvaris (NASDAQ: PHVS) plans multi-million-dollar stock sale - Stock Titan
Pharvaris (NASDAQ: PHVS) lines up $10.5M sale of founder stock - Stock Titan
Pharvaris (NASDAQ: PHVS) director plans nearly $2M stock sale in 2026 - Stock Titan
Founder shares in Pharvaris (NASDAQ: PHVS) set for $765K planned sale - Stock Titan
Pharvaris (NASDAQ: PHVS) director lines up new stock sale after recent trades - Stock Titan
Pharvaris N.V. (PHVS) exec sells 46,400 shares in cashless trade - Stock Titan
Souverijns Wim Executes Option Exercises and Sells 26,090 Pharvaris Shares - Kalkine Media
Officer at Pharvaris (NASDAQ: PHVS) plans potential $1.77M stock sale - Stock Titan
Director in Pharvaris (PHVS) lines up new sale after $300K stock trade - Stock Titan
Pharvaris (NASDAQ: PHVS) CEO sells 2,291 shares in 10b5-1 plan trade - Stock Titan
Pharvaris (NASDAQ: PHVS) exec files to sell shares from vested stock and options - Stock Titan
2,291 Pharvaris (Nasdaq: PHVS) shares set for resale - Stock Titan
(PHVS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Pharvaris Soars on Breakthrough Trial Win and Lofty Targets - TipRanks
Pharvaris (PHVS) Reports an 83% HAE Attack-Rate Reduction. Can Oral Convenience Win? - Yahoo Finance
Pharvaris N.V. (PHVS) Discusses Topline Results of Chapter-3 Phase III Study on Deucrictibant for Prophylactic Treatment of Hereditary AngioedemaSlideshow (NASDAQ:PHVS) 2026-09-10 - Seeking Alpha
Pharvaris (NASDAQ: PHVS) officer to sell 30,000 shares in September 2026 - Stock Titan
Pharvaris at Cantor Fitzgerald conference: oral HAE push gains momentum - investing.com
PHVS Maintained by Guggenheim -- Price Target Raised to $44.00 - GuruFocus
Guggenheim raises Pharvaris stock price target on trial results By Investing.com - Investing.com Nigeria
Guggenheim raises Pharvaris stock price target on trial results By Investing.com - Investing.com South Africa
Guggenheim raises Pharvaris stock price target on trial results - Investing.com
Guggenheim raises Pharvaris stock price target on trial results By Investing.com - Investing.com India
Guggenheim raises Pharvaris stock price target on trial results By Investing.com - Investing.com UK
Pharvaris at Wells Fargo conference: oral HAE drug gains ground - investing.com
Pharvaris at Wells Fargo conference: oral HAE drug gains ground By Investing.com - Investing.com Nigeria
symbol__ Stock Quote Price and Forecast - CNN
Wells Fargo raises Pharvaris stock price target on strong trial data - Investing.com Nigeria
Oppenheimer raises Pharvaris stock price target on trial results By Investing.com - Investing.com Australia
Pharvaris stock gets $60 target at H.C. Wainwright on trial data - Investing.com Nigeria
Pharvaris (NASDAQ: PHVS) director plans to sell shares from option exercise - Stock Titan
5.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):